Further, sCD163 and sMR has been evaluated alone and in combination with fibrosis markers in predictive scores for clinically significant portal hypertension [9, 10], and also as a predictor of decompensation and mortality in cirrhosis [7, 31, 32]. This evidence concerns the gene CD163 and liver disorder.